Nur Acar, MD (Istanbul, Turkey), Ziya Kapran, MD (Istanbul, Turkey), Yaprak Banu Unver, MD (Istanbul, Turkey), Tugrul Altan, MD (Istanbul, Turkey), Sezin Ozdogan, MD (Istanbul, Turkey)


To evaluate the safety and efficacy of 25-gauge transconjunctival sutureless vitrectomy (TSV) for the treatment of a variety of vitreoretinal diseases.


In this retrospective, interventional clinical trial, 64 consecutive eyes that underwent 25-gauge TSV between March 2004 to November2005 were evaluated. Eyes with grade C or greater proliferative vitreoretinopathy and severe diabetic traction retinal detachment in which extensive manipulation would be needed are excluded. Total surgical time, postoperative visual acuity (VA), intraocular pressure (IOP), postoperative inflammation and complications were the main outcome measures.


In all eyes vitrectomy was completed with 25-gauge instrumentation without any suturing. Mean surgical time was 34.20±10.26 minutes. No intraoperative complications were noted. Mean postoperative follow-up period was 2.90±2.32 months. Postoperatively, mean VA improved at 1st month and at the last visit (P: 001). Decrease in postoperative IOP was
found only at 2 hours (P: 0.000). Postoperatively, transient hypotony at 2 hours (n:4, 6.25%), vitreous hemorrhage (n:4, 6.25%) were noted. Retinal redetachment occurred in 1 (1.56%) eye necessitating revitrectomy. Endopthalmitis developed in 1 (1.56%) eye resulting a decrease in vision. There were no cases of choroidal detachment. No detectable inflammation was noted in any eyes by 4 weeks.


25-gauge TSV was observed to be effective for anatomical and functional recovery for a variety of vitreoretinal diseases. IOP decrease at 2 hours postoperatively is transient. Endophthalmitis, retinal detachment are possible vision-threathening complications.